Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $24,420.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 814 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total value of $24,420.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.

Enliven Therapeutics Stock Up 0.0 %

Shares of NASDAQ ELVN opened at $28.98 on Friday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -15.02 and a beta of 1.10. The stock’s fifty day simple moving average is $24.62 and its 200 day simple moving average is $22.93.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter valued at $256,000. The Manufacturers Life Insurance Company purchased a new stake in Enliven Therapeutics in the 2nd quarter worth about $322,000. Marshall Wace LLP acquired a new stake in Enliven Therapeutics during the 2nd quarter worth about $4,489,000. First Turn Management LLC purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $9,657,000. Finally, Nicholas Investment Partners LP acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at about $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.